13 Apr 2022 , 03:08 PM
The company announced that it received the Prior Approval Supplement (PAS) Approval from the US Food and Drug Administration (USFDA), which allows for a site transfer and manufacturing of the drug at Jarod.
This product is indicated for the short-term treatment of a breathing problem (Apnea) in premature infants. Caffeine blocks certain proteins (adenosine receptors) which leads to improved breathing in these infants.
Sagent Pharmaceuticals, Inc. (Sagent), a Nichi-Iko Group Company, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing, and marketing pharmaceutical products for the North American market, with a specific emphasis on injectables.
Prior Approval Supplement (PAS)
A Prior Approval Supplement (PAS) is an application which seeks to make changes to an already approved application, such as an Abbreviated New Drug Application (ANDA), which is used by the USFDA to approve generic drugs.
At around 3:09 PM, Zydus Lifesciences was trading at Rs364.85 apiece up by Rs1.75 or 0.48% on the BSE.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.